All the Drug Class Drugs
GnRH Antagonist. Cetrorelix (as acetate) 0.25 mg/vial. Powder and solv. for SC. inj. 0.25 mg/ vial . Once daily, first dose to be admin. under med. supervision.
Preven. of premat. ovul. in pts. undergoing a contr. ovarian stimul. for IVF.
C/I: Hypersens. to the act. subst. or any struct. analogues of GnRH, extrins. pept. hnes., mannitol.
• pregn. and lact.
• sev. renal impair
GnRH Antagonist. Degarelix (as Acetate) 80 mg, 120 mg. VIALS (pwdr. for sol. for inject.): 1 x 80
mg + 1 vial solv; 2 x 120 mg + 2 vials
solv. S.C. inject. into abdom. reg. over
18 yrs. See lit. Initial: 240 mg as 2 S.C.
injects (120 mg ea.), then 80 mg S.C. 1
x month.
Adult male pts. with advanced hormonedepend. prostate cancer.
C/I: Hypersens.
GnRH Antagonist, Gonadotropin Releasing Hormone Analogues. Ganirelix 0.25 mg. Pre-filled syr. with sol. for SC inj. 1 X 0.5 ml
To be admin. once/d, starting on day 5 or day 6 of FSH or corifollitropin alfa admin. Daily tmt. to be continued up to the day that sufficient follicles of adequate size are present. See full prescript. info.
Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian stimul. in the setting of fertility tmts.
C/I: Hypersens. incl. to gonadotrophin-releasing homrone (GnRH) or analogue/
Mod. or sev. impairm. of renal or hepatic function/ Pregn. or lactation.
GnRH Antagonist. Ganirelix 0.25 mg / 0.5 ml. PRE-FILLED SYRINGE: 1, 5. To be
prescribed only by a specialist in tmt. of
infertil. Admin. S.C. in upper leg. Start at
day 2 or 3 of menses, 0.25 mg S.C. 1 x dly
on day 6 of FSH admin. See lit.
Prevent. prem. luteiniz. hormone (LH)
surges in women undergoing controlled
ovarian hyperstim. (COH) for assisted
reproduct. techniques (ART).
C/I: Hypersens., to compon., to
gonadotrophin-release. hormone
(GnRH) or any other GnRH analgoue,
mod- severe impaired ren. or hepat.
funct., pregn., lact.
GnRH Antagonist. Elagolix (as sodium) 150 mg, 200 mg. F.C. TABS: 28×150mg, 56×200mg. Init. tmt. with 150 mg×1/d, max. tmt. duration-24 mnths.
Consider initiat. tmt. with 200 mg×2/d max. tmt. duration- 6 mnths., with coexist. cond.- dyspareunia.
Init. tmt. with Elagolix 150 mg×1/d. Use of 200 mg×2/d is not recommended, max. tmt. duration- 6 mnths., with coexist. cond.- moder. hep. impair. (Child-Pugh Class B).
Hep. Impair.: No dosage adjust. of Elagolix is require. in women with mild hep. impair. (Child-Pugh A). Elagolix 150 mg×1/d is recomm. for women with moder. hep. impair. (Child-Pugh B) with the duration of tmt. limited to 6 mnths. Use of Elagolix 200 mg×2/d is not recommend. for women with moder. hep. impair. See lit.
Management of moder.–seve. pain assoc. with endometriosis.
C/I: With Hypersens. Preg. Women with known osteoporosis. Women with sev. hep. impair (Child-Pugh C). Concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil).
IL-ELAG-200027-Sep. 2020
